Intellipharmaceutics International Inc. (NASDAQ:IPCI) released its earnings results on Friday. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.07). Intellipharmaceutics International had a negative return on equity of 832.00% and a negative net margin of 325.20%.
Shares of Intellipharmaceutics International (NASDAQ:IPCI) opened at 2.86 on Monday. Intellipharmaceutics International has a 1-year low of $1.41 and a 1-year high of $3.33. The company has a 50-day moving average price of $2.09 and a 200 day moving average price of $1.87. The firm’s market capitalization is $82.22 million.
IPCI has been the topic of several analyst reports. Maxim Group set a $6.00 target price on Intellipharmaceutics International and gave the stock a “buy” rating in a report on Thursday, October 6th. Zacks Investment Research raised Intellipharmaceutics International from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Tuesday, September 13th. Finally, Brean Capital initiated coverage on Intellipharmaceutics International in a report on Monday, October 3rd. They set a “buy” rating and a $8.00 target price on the stock.
About Intellipharmaceutics International
IntelliPharmaCeutics International Inc is a Canada-based pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.